Table 3.
Observed distribution of HR-HPV infections and detected CIN2+, by HR-HPV genotype and the woman’s age
| Age group | |||||
|---|---|---|---|---|---|
| 24–29 | 30–49 | 50–64 | Total | ||
| N screened | 23,864 (100%) | 72,833 (100%) | 30,541 (100%) | 127,238 (100%) | |
| HR-HPV genotype at baseline | |||||
| HR-HPV infections | HR-HPV+ | 6709 (28%) | 7646 (10%) | 1742 (6%) | 16,097 (13%) |
| HPV 16+ | 2111 (9%) | 1588 (2%) | 348 (1%) | 4047 (3%) | |
| Else HPV 18+ | 509 (2%) | 541 (1%) | 110 (<1%) | 1160 (1%) | |
| Else other HR-HPV+ | 4089 (17%) | 5517 (8%) | 1284 (4%) | 10,890 (9%) | |
| Colposcopies | HR-HPV+ | 4013 (17%) | 3890 (5%) | 856 (3%) | 8759 (7%) |
| HPV 16+ | 1649 (7%) | 1125 (2%) | 215 (1%) | 2989 (2%) | |
| Else HPV 18+ | 364 (2%) | 325 (<1%) | 61 (<1%) | 750 (1%) | |
| Else other HR-HPV+ | 2000 (8%) | 2440 (3%) | 580 (2%) | 5020 (4%) | |
| CIN2+ | HR-HPV+ | 1579 (7%) | 1133 (2%) | 147 (<1%) | 2859 (2%) |
| HPV 16+ | 899 (4%) | 475 (1%) | 49 (<1%) | 1423 (1%) | |
| Else HPV 18+ | 138 (1%) | 95 (<1%) | 14 (<1%) | 247 (<1%) | |
| Else other HR-HPV+ | 542 (2%) | 563 (1%) | 84 (<1%) | 1189 (1%) | |
| CIN3+ | HR-HPV+ | 980 (4%) | 699 (1%) | 84 (<1%) | 1763 (1%) |
| HPV 16+ | 613 (3%) | 324 (<1%) | 31 (<1%) | 968 (1%) | |
| Else HPV 18+ | 82 (<1%) | 62 (<1%) | 9 (<1%) | 153 (<1%) | |
| Else other HR-HPV+ | 285 (1%) | 313 (<1%) | 44 (<1%) | 642 (1%) | |
CIN cervical intraepithelial neoplasia, HR-HPV high-risk human papillomavirus